LORBRENA

This brand name is authorized in Brazil, Canada, Ecuador, Japan, United States

Active ingredients

The drug LORBRENA contains one active pharmaceutical ingredient (API):

1 Lorlatinib UNII OSP71S83EU - LORLATINIB

Lorlatinib is a selective, adenosine triphosphate (ATP)-competitive inhibitor of ALK and c-ros oncogene 1 (ROS1) tyrosine kinases. Read about Lorlatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LORBRENA Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01ED05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01ED Anaplastic lymphoma kinase (ALK) inhibitors
Discover more medicines within L01ED05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522720080089407, 522720080089507
Country: CA	Health Products and Food Branch	Identifier(s): 02485966, 02485974
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 6764-MEE-1121, 6789-MEE-1221
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291055F1020, 4291055F2027
Country: US	FDA, National Drug Code	Identifier(s): 0069-0227, 0069-0231